Impact of established prognostic factors and molecular subtype in very young breast cancer patients: Pooled analysis of four EORTC randomized controlled trials

Breast Cancer Research

Volumn 13, Issue 3, 2011, Pages

  Van Der Hage, Jos A ^a   Mieog, J Sven D ^b   Van De Velde, Cornelis J H ^b   Putter, Hein ^b   Bartelink, Harry ^a   Van De Vijver, Marc J ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PARAFFIN;

AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; OVERALL SURVIVAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TISSUE MICROARRAY; TUMOR CLASSIFICATION; ADJUVANT CHEMOTHERAPY; ADULT; BREAST TUMOR; FEMALE; META ANALYSIS (TOPIC); MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 79959383019     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2908     Document Type: Article

References (39)

1. Winchester DP. Breast cancer in young women. Surg Clin North Am 1996, 76:279-287. 10.1016/S0039-6109(05)70439-4, 8610264.
2. Cancer Research UK: News & Resources. , http://info.cancerresearchuk.org
3. Knowledge Network Dutch Cancer Centers. , http://www.ikcnet.nl
4. Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 2001, 44-51.
5. de Bock GH, van der Hage JA, Putter H, Bonnema J, Bartelink H, van de Velde CJH. Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer 2006, 42:351-356. 10.1016/j.ejca.2005.10.006, 16314086.
6. Elkhuizen PH, Voogd AC, van den Broek LC, Tan IT, van Houwelingen HC, Leer JW, van de Velde CJH. Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. Int J Radiat Oncol Biol Phys 1999, 45:73-83. 10.1016/S0360-3016(99)00158-3, 10477009.
7. Shannon C, Smith IE. Breast cancer in adolescents and young women. Eur J Cancer 2003, 39:2632-2642. 10.1016/S0959-8049(03)00669-5, 14642925.
8. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert WF, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, Collette L, Pierart M. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001, 345:1378-1387. 10.1056/NEJMoa010874, 11794170.
9. Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, Luini A, Veronesi P, Intra M, Orecchia R, Catalano G, Galimberti V, Nole F, Martinelli G, Goldhirsch A. Very young women (< 35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 2002, 13:273-279. 10.1093/annonc/mdf039, 12401701.
10. Maggard MA, O'Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY. Do young breast cancer patients have worse outcomes?. J Surg Res 2003, 113:109-113. 10.1016/S0022-4804(03)00179-3, 12943818.
11. Choi DH, Lee MH, Bale AE, Carter D, Haffty BG. Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 2004, 22:1638-1645. 10.1200/JCO.2004.04.179, 15117986.
12. Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 2001, 93:1215-1223. 10.1093/jnci/93.16.1215, 11504767.
13. de Sanjose S, Leone M, Berez V, Izquierdo A, Font R, Brunet JM, Louat T, Vilardell L, Borras J, Viladiu P, Bosch FX, Lenoir GM, Sinilnikova OM. Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int J Cancer 2003, 106:588-593. 10.1002/ijc.11271, 12845657.
14. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008, 26:3324-3330. 10.1200/JCO.2007.14.2471, 18612148.
15. Anders CK, Acharya CR, Hsu DS, Broadwater G, Garman K, Foekens JA, Zhang Y, Wang Y, Marcom K, Marks JR, Mukherjee S, Nevins JR, Blackwell KL, Potti A. Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One 2008, 3:e1373. 10.1371/journal.pone.0001373, 2148101, 18167534.
16. van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, van der Schueren E, Helle PA, van Zijl K, Bartelink H. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000, 92:1143-1150. 10.1093/jnci/92.14.1143, 10904087.
17. van der Hage JA, van de Velde CJH, Julien JP, Floiras JL, Delozier T, Vandervelden C, Duchateau L. Improved survival after one course of perioperative chemotherapy in early breast cancer patients. long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854. Eur J Cancer 2001, 37:2184-2193. 10.1016/S0959-8049(01)00294-5, 11677105.
18. van der Hage JA, van de Velde CJH, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001, 19:4224-4237.
19. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert WF, Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Warlam-Rodenhuis CC, Pierart M, Collette L. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007, 25:3259-3265. 10.1200/JCO.2007.11.4991, 17577015.
20. van Nes JG, Putter H, Julien JP, Tubiana-Hulin M, van de Vijver MJ, Bogaerts J, de Vos M, van de Velde CJ, . Cooperating Investigators of the EORTC Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat 2009, 115:101-113. 10.1007/s10549-008-0050-1, 18484198, Cooperating Investigators of the EORTC.
21. Bubendorf L, Nocito A, Moch H, Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 2001, 195:72-79. 10.1002/path.893, 11568893.
22. Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, Kuo D, Brennan MF, Lewis JJ, Cordon-Cardo C. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001, 158:1245-1251. 10.1016/S0002-9440(10)64075-8, 1891917, 11290542.
23. Mueller-Holzner E, Fink V, Frede T, Marth C. Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor. Breast Cancer Res Treat 2001, 69:13-19. 10.1023/A:1012281221647, 11759824.
24. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001, 10:657-662. 10.1093/hmg/10.7.657, 11257096.
25. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
26. van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van de Velde CJ, van de Vijver MJ. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 1996, 74:78-85. 10.1038/bjc.1996.319, 2074622, 8679463.
27. Clahsen PC, van de Velde CJH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek LC, Sahmoud TM, van de Vijver MJ. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998, 16:470-479.
28. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988, 319:1239-1245. 10.1056/NEJM198811103191902, 2903446.
29. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Veronesi P, Torrisi R, Montagna E, Luini A, Intra M, Gentilini O, Ghisini R, Goldhirsch A, Colleoni M. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (< 35 years) with operable breast cancer. Ann Oncol 2010, 21:1974-1981. 10.1093/annonc/mdq072, 20332136.
30. Sundquist M, Thorstenson S, Brudin L, Wingren S, Nordenskjold B. Incidence and prognosis in early onset breast cancer. Breast 2002, 11:30-35. 10.1054/brst.2001.0358, 14965642.
31. Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW. Early-onset breast cancer--histopathological and prognostic considerations. Br J Cancer 1997, 75:1318-1323. 10.1038/bjc.1997.223, 2228226, 9155052.
32. Jones HA, Antonini N, Hart AA, Peterse JL, Horiot JC, Collin F, Poortmans PM, Oei SB, Collette L, Struikmans H, Van den Bogaert WF, Fourquet A, Jager JJ, Schinagl DA, Warlam-Rodenhuis CC, Bartelink H. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol 2009, 27:4939-4947. 10.1200/JCO.2008.21.5764, 2799051, 19720914.
33. van der Hage JA, Mieog JS, van der Vijver MJ, van de Velde CJH. Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis. Breast Cancer Res 2007, 9:R70. 10.1186/bcr1778, 2242667, 17931406.
34. Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. J Clin Oncol 2007, 25:2360-2368. 10.1200/JCO.2006.10.3754, 17515570.
35. Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007, 369:1711-1723.
36. Jonat W, Pritchard KI, Sainsbury R, Klijn JG. Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient. J Cancer Res Clin Oncol 2006, 132:275-286. 10.1007/s00432-006-0082-z, 16435142.
37. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
38. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009. 10.1056/NEJMoa021967, 12490681.
39. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.